Comparison of Effectiveness of Dapoxetine vs Placebo for Prolonging Intra Vaginal Ejaculatory Latency Time in Premature Ejaculation
DOI:
https://doi.org/10.52206/jsmc.2019.9.1.%25pKeywords:
dapoxetine, placebo, intra vaginal ejaculatory, latency time, premature ejaculationAbstract
Background: Premature ejaculation (PE) is inability to delay ejaculation sufficiently to enjoy love making which manifests asoccurrence of ejaculation before or very soon after the beginning of intercourse†1PE concentrate on three criteria: shortened or
nonexistent intravaginal ejaculatory latency time (IELT), usually less than 2 minutes; reduced control over ejaculation; and
decreased satisfaction with intercourse.
Objective: To Compare the effectiveness of dapoxetine versus placebo for prolonging intra vaginal ejaculatory latency time in
premature ejaculation.
Material & Methods: This study was conducted at Department of Urology, institute of Kidney Diseases Hayatabad Medical
Complex, Peshawar. Study Design was randomized controlled trial. Duration of the study was six months (27/2/2015 to 27/8/2015). In this study a total of 188 patients were observed by taking 94 in each group, using 56.5% proportion of improvement in ejaculatory time with Dapoxetine and 35.4% improvement in control group5, 95% confidence interval, 5% level of significance and 90% power of the test with non probability consecutive sampling.
Results: This study shows that in Group A (Dapoxetine) mean age was 33 ± 10.831. Where as in Group B (Placebo) mean age was 32 ± 10.458. More over Dapoxetine was effective in 64(68%) patients while Placebo was effective in 35(37%) patients.
Conclusion: Our study concludes that dapoxetine was more effective than placebo for prolonging intra vaginal ejaculatory in term of latency time in premature ejaculation.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
